We have previously demonstrated that ClC-3 chloride channel activity and expression are significantly increased in remodelled cerebral vessels of hypertensive rats. This study aims to examine whether this channel directly regulates cerebrovascular remodelling during hypertension by using ClC-3 2/2 mice.
Introduction
Cerebrovascular remodelling during hypertension, which decreases or interrupts cerebral blood flow, is considered as a major risk factor for stroke.
1 While the precise mechanisms of cerebrovascular remodelling are not fully understood, it is generally accepted that the co-ordination of vascular smooth muscle cell (VSMC) proliferation, apoptosis, migration, and extracellular matrix accumulation that leads to a significant increase in wall thickness and decrease in lumen diameter, is an essential contributor to the hypertrophic remodelling of cerebral arterioles. 2, 3 Recent growing evidence has demonstrated that volume-regulated Cl 2 channel (VRCC) plays a key role in the regulation of cell volume, proliferation, and apoptosis, 4 especially in VSMCs. 5 Although the molecular nature of VRCC remains to be conclusively identified, a series of independent studies from many laboratories have established that ClC-3, a member of the voltage-gated ClC chloride channel family, is the key component of VRCC in cardiac myocyte. 6, 7 In VSMCs, we have further demonstrated that ClC-3 protein is the molecular gene of VRCC 8, 9 and mediates endothelin-1(ET-1)-induced proliferation 10 and H 2 O 2 -induced apoptosis in the rat basilar artery smooth muscle † These authors contributed equally to this work.
cells (BASMCs). 11 Moreover, we also found that ClC-3 channel activity and protein expression are significantly increased in BASMCs from 2-kidney 2-clip stroke-prone renovascular hypertensive rats, and its increments parallel the severity of cerebrovascular remodelling, 12 suggesting that ClC-3 is implicated in vascular remodelling during chronic hypertension. This perspective is further supported by our more recent finding that simvastatin ameliorates hypertension-induced cerebrovascular remodelling through inhibition of cerebrovascular smooth muscle cells proliferation by suppression of ClC-3 chloride channel activity. 13 However, the direct effect of endogenous ClC-3 chloride channel on cerebrovascular remodelling and the underlying mechanisms are still unknown.
In the present study, we therefore determined the functional role of ClC-3 in the development of cerebrovascular remodelling by using ClC-3 knock-out (ClC-3 2/2 ) mice treated with DOCA-salt, a low-renin salt-sensitive hypertension model. Our results showed that ClC-3 deficiency attenuates cerebrovascular remodelling via reduction of MMPs/ TIMP expression, and suppression of the TGF-b1/Smad3 signalling pathway in this low-renin hypertension.
Methods

Animals
ClC-3 2/2 mice and its corresponding ClC-3 +/+ controls of 129/SvJ-C57BL/ 6 background, as kind gifts of Dr Duan (University of Nevada, School of Medicine, Reno, NV, USA), were bred in house. 14 All mice were housed under controlled environmental conditions and maintained with standard food and water. All animal procedures were in accordance with the policies of the Animal Care and Use Committee, Sun Yat-Sen University, and conformed to the 'Guide for the Care and Use of Laboratory Animals' of the National Institute of Health In China.
DOCA-salt hypertension
DOCA-salt hypertension was created as we described previously. 15 Briefly, ClC-3 +/+ wild-type (WT) and ClC-3 2/2 mice (20-25 g) were anaesthetized with pentobarbital (60 mg/kg, intraperitoneally). Then they underwent left unilateral nephrectomy. After 2 weeks of recovery, a 50 mg pellet of DOCA (21-day release, Innovative Research of America, Sarasota, FL, USA) was implanted subcutaneously by incision of the right flank. DOCAsalt mice were given water containing 1.2% NaCl and 0.2% KCl starting from the first day of DOCA treatment. Sham mice were also uninephrectomized but received no DOCA implant and were given tap water. To exclude the possible effect of blood pressure elevation on remodelling, a set of WT DOCA-salt mice were treated with b1 receptor antagonist propranolol (250 mg/kg/day) in drinking water after 1 week with DOCA-salt regimen. Average systolic blood pressure (SBP) was measured by non-invasive, tailcuff method (tail-cuff plethysmography, AD instruments, Australia) as previously described. 15 All of the tissues were collected 3 weeks after DOCA-salt implantation, after the mice were sacrificed by overdose of pentobarbital intraperitoneally.
Tissue preparation and immunohistochemistry analysis
Mice were perfusion-fixed at a constant pressure (100 mmHg) via the left ventricle with Krebs solution, followed by 4% freshly depolymerized paraformaldehyde for 10 min. The brains were carefully removed and sections (8 mm) of freshly frozen basilar arteries were prepared as previously described. 12, 13 Immunohistochemistry was then performed to detect the expression of vascular smooth muscle a-actin. Briefly, five randomly selected sections in each group were exposed to primary a-actin antibody (1:400, Sigma) at 48C overnight, followed by the incubation with secondary goat anti-mouse antibody. In negative controls, normal goat serum in PBS was substituted for the primary antibody. Positive immunostaining was determined with Boster SABC kit and visualized with diaminobenzidine substrate (Boster Bio-Engineering), followed by counterstaining with haematoxylin (Sigma).
Morphological assessment
The cryosections of basilar arteries stained with a-actin were used for morphometric analysis. The circumferences (C) of external elastic lamina (EEL) and internal elastic lamina (IEL) were measured with Carl Zeiss Axiovison software. External (De) and internal (Di) diameters were calculated as C/ p assuming a circular structure at maximal vasodilatation, and medial crosssectional area (CSA) was obtained by subtraction of the internal CSA from external CSA:
). The media thickness, lumen diameter, media -lumen ratio, and medial CSA were calculated to assess the degree of remodelling. Data from five sections per animal were averaged.
Electron microscopy
After mice were perfusion-fixed transcardially as previously reported, 13 the brains were removed, and the tissue blocks containing the basilar artery at midpoint were cut into cubes of 1 × 1 × 3 mm. Ultrathin sections with thickness of 80 -100 nm were prepared and stained with uranyl acetate and lead citrate, and then were viewed under a transmission electron microscope (FEI TECNAI spirit G2, USA).
Immunofluorescence analysis
Immunofluorescence was performed to detect the expression of fibronectin, an extracellular matrix (ECM) glycoprotein that contributes to vascular remodelling. Frozen sections were incubated with primary anti-mouse fibronectin monoclonal antibody (1:200; Calbiochem, Merck, Germany) at 48C overnight, then reacted with Alexa Fluorw 594 goat anti-mouse IgG (1:200, Molecular Probes, OR, USA) at room temperature for 1 h. Sections incubated with phosphate buffer, instead of the primary antibodies, were used as negative control. All sections were analysed using confocal system (OLYMPUS, FV500-IX 81, magnification × 400) and Image-Pro Plus 5.0. For each tested group, five mouse brains were taken for the experiment, respectively.
Western blot analysis
Western blot was performed as described previously. 16 Basilar arteries were homogenized and protein contents were measured using the BCA protein assay (Pierce, Rockford, IL, USA). After blocking 1 h at room temperature in 5% milk solution, the membranes were probed overnight with the following primary antibodies, respectively: anti-MMP-2, anti-MMP-9 (matrix metalloproteinases, Calbiochem, Merck, Germany), anti-MT1-MMP (membrane-type MMPs, Calbiochem, Merck, Germany), anti-TIMP-2 (tissue inhibitor of metalloproteinases, Chemicon, USA), antiSmad3 (1:500, Cell Signaling Technology), and anti-phospho-Smad3 (ser423/425) (1:200, Cell Signaling Technology). After secondary antibodies were applied, final detection was carried out with LumiGLO chemiluminescent reagent (New England Biolabs) as described by the manufacturer. Protein expression was normalized to b-actin or GADPH.
Enzyme-linked immunosorbent assay
The amount of transforming growth factor b1 (TGF-b1) in the serum was determined by using an ELISA kit (Quantikine, R&D systems, USA) specifically designed for quantitative determination of activated mouse TGF-b1 concentration in the serum.
Statistical analysis
All of the values were expressed as mean + SEM. Comparisons between two groups were analysed using Student's t test. When .2 treatment groups were compared, one-way ANOVA was used. Values of P , 0.05 were considered statistically significant.
ClC-3 and cerebrovascular remodelling 3. Results
Effect of ClC-3 deficiency on blood pressure and body weight
The effects of ClC-3 deficiency on blood pressure (BP) responses to DOCA-salt in mice were shown in Supplementary material online, Figure S1 . There were no significant differences in baseline BP (0 week) among the groups. Compared with that in sham mice, systolic BP in WT DOCA-salt mice was significantly increased over a 3-week period (99.4 + 3.1 vs. 144.9 + 6.2 mmHg at day 21, P , 0.01), which was significantly inhibited in ClC-3 2/2 DOCA-salt mice starting from day 7
(112.9 + 3.2 vs. 120.7 + 8.5 mmHg, P , 0.05) and continuing through day 21 (121. mice before and after DOCA-salt treatment (data not shown).
ClC-3 deficiency prevents cerebrovascular remodelling
As indicated by a-actin staining of the smooth muscle layer ( Figure 1A) , DOCA-salt treatment led to a significant increase in media thickness and decrease in internal lumen diameter, resulting in increased media-to-lumen ratio in basilar arteries from WT mice relative to controls at 3 weeks. Medial CSA was also significantly enhanced in WT DOCA-salt mice, a typical feature of hypertrophic remodelling. Although propranolol effectively lowered BP in WT DOCA-salt mice, it was unable to reverse the morphological changes of basilar artery. In contrast, vascular structure alterations were significantly attenuated in ClC-3 2/2 DOCA-salt mice ( Figure 1B 
-E).
Further electron microscopic observation demonstrated migration and disarray of SMCs in the thickened medial layer of basilar artery in WT DOCA-salt mice, and increased accumulation of ECM protein in the widened intercellular space. Necrosis of SMCs was also observed in our study. However, there was no apparent endothelial cells damage ( Figure 2) . Loss of ClC-3, but not treatment with propranolol, significantly attenuated the above vascular ultra-structural alterations.
Lack of ClC-3 reduces expression of fibronectin
Representative photomicrographs of immunofluorescence indicated that fibronectin staining was weakly presented in basilar arteries from sham mice. In arteries from WT DOCA-salt mice, strong fibronectin staining was scattered in the media mainly under the endothelium, and this was markedly reduced in ClC-3 2/2 DOCA-salt mice ( Figure 3 ).
Effect of ClC-3 deficiency on expression of MMPs/TIMPs
As illustrated in Figure 4 , DOCA-salt produced a significant increase in protein expression of MMP-2 and its activator MT1-MMP (MMP-14) in basilar arteries from both WT and ClC-3 2/2 mice compared with their sham controls, but this increase in both MMPs in ClC-3 2/2 mice was much lower than that in WT mice. Moreover, TIMP-2, an inhibitor for MMP-2, was also up-regulated by DOCA-salt in WT mice compared with sham controls, which was significantly reduced in DOCA-salttreated ClC-3 2/2 mice. However, the expression of MMP-9 was at undetected level in both mouse strains with or without DOCA-salt treatment (data not shown), suggesting a lower expression and function of MMP-9 than MMP-2 in the basilar artery.
3.5 Effect of ClC-3 deficiency on serum TGF-b1 level
Because TGF-b1 has been reported to play an important role in cardiovascular remodelling, we therefore tested the concentration of TGF-b1 in serum among groups. As shown in Figure 5 , DOCA-salt treatment induced a significant increase in TGF-b1 level in serum compared with sham controls in WT mice, which was markedly reduced by ClC-3 deficiency.
Effect of ClC-3 deficiency on Smad3 phosphorylation
Since Smad3 phosphorylation is known to play a crucial role in TGF-b-induced pathological remodelling, we further determined the expression of total Smad3 and its phosphorylation. Our results showed that total Smad3 expression was similar between WT and ClC-3 2/2 sham mice, and DOCA-salt treatment significantly upregulated the total Smad3 expression in both mouse strains. Interestingly, although there was no difference in the total Smad3 expression between the two mouse strains after DOCA-salt regimen, the phosphorylated Smad3 level was only significantly increased in DOCA-salttreated WT mice, but not in ClC-3 2/2 mice ( Figure 6 ). These results suggest that the activation of TGF-b1/Smad3 signalling pathway may be involved in cerebrovascular remodelling induced by DOCA-salt hypertension, while ClC-3 deficiency protected the basilar artery against remodelling possibly by the inhibition of TGF-b1 and its downstream signalling pathway.
Discussion
In the present study, to the best of our knowledge, we demonstrated the following changes for the first time: (i) in vivo ClC-3 knockout significantly prevented the progression of hypertension induced by DOCA-salt; (ii) in DOCA/salt hypertension, cerebral basilar artery underwent hypertrophic remodelling, which was inhibited in DOCA-salt treated ClC-3 2/2 mice independent of blood pressure; and (iii) DOCA/salt induced cerebrovascular remodelling was accompanied by increased extracellular matrix deposition, MMP expression, and activation of TGF-b1/Smad3 signalling pathway. ClC-3 deficiency inhibited cerebrovascular remodelling possibly via suppression of MMP and TGF-b1/ Smad3 signalling pathway. Cerebrovascular remodelling, an adaptive response to increased BP, is a prominent feature of hypertension and considered as a major risk factor for stroke. It has been reported that small resistant arteries, including cerebral arterioles, undergo hypertrophic inward remodelling during chronic hypertension, characterized by a significant increase in the medial CSA of the vessel wall with a reduction in lumen diameter. These structural alterations lead to the impairment of cerebral vasodilation, 17, 18 and may be one of the major contributors to stroke. It has been reported that DOCA could induce deleterious remodelling of middle cerebral artery and exacerbate the damage caused by cerebral ischaemia ClC-3 and cerebrovascular remodelling in experimental hypertensive rats. 19 In our present study, we found that the basilar artery exhibited a decreased lumen diameter and increased medial thickness, media-to-lumen ratio, and medial CSA in mice after 3 weeks of DOCA-salt treatment, suggesting that the basilar artery underwent inward hypertrophic remodelling. These vascular structural changes were consistent with what we previously observed in mouse resistant mesenteric artery in the same hypertension model. 15 In addition, our previous work in 2-kidney 2-clip (2k2c) hypertensive rats also showed similar structural alterations in cerebral basilar artery. 12, 13 In 2k2c hypertension, 13 VSMCs proliferation played an important role in cerebrovascular remodelling. However, our present results of vascular ultra-structure by electron microscopy revealed that the remodelling of cerebrovascular wall in DOCA-salt mice was mainly due to the accumulation of extracellular matrix and the disarray of VSMCs, whereas VSMCs proliferation was not apparently observed. Moreover, the results by immunofluorescence also showed that the expression of ECM protein fibronection was significantly increased in basilar artery of DOCA-salt mice, indicating the importance of ECM deposition in vascular remodelling in this hypertension model. These results suggest that the ultrastructural changes of vessels responsible for vascular remodelling may be altered with different hypertension models. As the most prominent molecular candidate of VRCC in VSMCs, ClC-3 has been demonstrated to regulate both cell proliferation and apoptosis in VSMCs. 10, 11 Our previous study in 2k2c hypertensive rats also showed that the VRCC activity as well as the expression of ClC-3 protein is increased in BASMCs, and this increment parallels the development of cerebrovascular remodelling. 12, 13 Moreover, administration of simvastatin could ameliorate the vascular structure alterations in this model, and this effect is associated with the inhibition of ClC-3 expression. 13 All of these results strongly indicate that ClC-3 contributes to the cerebrovascular remodelling during hypertension. However, direct evidence of whether ClC-3 could influence cerebrovascular remodelling in vivo is still lacking. To fill this gap, our present study provided a very interesting new finding that cerebrovascular remodelling observed in WT DOCA-salt mice could be prevented by ClC-3 gene disruption, giving convincing evidence that ClC-3 is an important regulator for vascular remodelling. Hence, the ability to protect cerebral vessels against remodelling during hypertension by ClC-3 inhibition may provide a basis for a new strategy to combat the development of stroke.
It is important to note that in our results, ClC-3 knockout not only ameliorated the structural alteration of cerebral vessels but also decreased BP. To exclude the possibility that the beneficial role of ClC-3 deficiency in cerebrovascular remodelling is merely secondary to its effect on BP, propranolol, a non-selective beta-receptor blocker, was used as a comparison. Our results showed that propranolol produced a substantial reduction in arterial pressure in WT DOCA-salt mice, consistent with the recent report that propranolol could effectively decrease mean arterial pressure in salt-sensitive hypertension. 20 However, it is interesting that although propranolol and ClC-3 deficiency produced similar BP lowering effect, the cerebrovascular remodelling induced by hypertension was reversed only in ClC-3 2/2 mice.
These findings indicate that effects of ClC-3 deficiency on remodelling of cerebral basilar artery may be largely independent of reductions in arterial pressure, and instead may be a direct effect of ClC-3 inhibition. Lowering of BP per se is not sufficient to rescue vascular remodelling in hypertension. Several other studies have also reported that propranolol, or other anti-hypertensive drugs such as hydralazine, did not appear to exert a significant protective effect on cerebral arterioles remodelling in stroke-prone spontaneously hypertensive rat, even though it effectively reduced arterial pressure. 21, 22 The present findings also suggest that ClC-3 may be an important determinant of vascular remodelling during chronic hypertension. Thus, it is of great significance that ClC-3 Figure 2 Transmission electron microscopy images of mouse cerebral basilar arteries from WT and ClC-3
2/2 mice with or without DOCA-salt implantation. DOCA-salt resulted in smooth muscle cell necrosis, disarrangement, intercellular space enlargement, and collagen fibres deposition in WT mice (black arrows); while endothelium and their junctions were still intact. Lack of ClC-3, but not propranolol, reversed these ultrastructural changes. Original magnification ×5800. Bar ¼ 2 mm.
not only regulates BP but also plays a pivotal direct role in cerebrovascular remodelling independent of BP in this hypertension model. An increase in extracellular matrix in cerebral vessels is a typical feature and responsible for the altered vascular structure during chronic hypertension. 23 The deposition of ECM may not only directly lead to the growth of media, but also facilitate the proliferation and migration of VSMCs. Among various ECM proteins, fibronectin has been demonstrated to play a fundamental role in vascular remodelling. 24, 25 It has been reported that increased expression of fibronectin accounts for altered vascular structure in DOCA-salt, 26 SHR, 27 Dahl saltsensitive, 28 and angiotensin II-induced hypertension. 29 Therefore, we further examined fibronectin expression by immunofluorescence assay. Our present study provides a new finding that in cerebral vessels of DOCA-salt mice, fibronectin contributes to vascular hypertrophic remodelling, which is blunted in ClC-3 2/2 mice, suggesting that ClC-3 deficiency may exert its protective effect on vascular structure by inhibiting fibronectin deposition. Matrix metalloproteinases (MMPs) are a family of structurally related, zinc-containing enzymes that serve an important role in vascular remodelling by degrading and re-organizing the ECM and connective tissue proteins. 30 The proteolytic effects of MMPs also promote the migration and re-arrangement of VSMC. 31 In both clinical patients and animal models ClC-3 and cerebrovascular remodelling of hypertension, increased MMP-2 32 or MMP-9 33 levels have been observed and recognized as the principal inducer of vascular remodelling. 34 In addition, it has been previously reported that the expression of MT1-MMP could specifically induce MMP-2 activation, whereas TIMP-2 is a known inhibitor of MMP-2. 30 It has been generally accepted that the imbalance between the function of MMPs and TIMPs plays an important role in the abnormal ECM degradation and re-organization, and thus contributes to the remodelling of the vessel wall in hypertension. We therefore examined whether the regulation of MMP/TIMP is involved in the beneficial effect of ClC-3 absence on cerebrovascular remodelling. In our present study, we found that treatment with DOCAsalt for 3 weeks significantly up-regulated the expression of MMP-2 and MT1-MMP in basilar artery of WT mice. However, unlike MMP-2, the expression of MMP-9 was barely detectable in vessels of both sham control and DOCA-salt hypertensive mice. These results suggest that MMP-2, but not MMP-9, may play an essential role in cerebrovascular remodelling in this hypertension model. A previous study by others also showed that there is significantly increased MMP-2 but much lower MMP-9 expression and activity in aortas of DOCA-salt hypertensive rats. 32 In the present study, the increase in TIMP-2 expression observed in WT hypertensive mice is presumably an adaptive response to the higher-than-normal levels of MMP-2. The up-regulation of MMP-2 may lead to the degradation of normal vascular connective tissues, thus promoting VSMCs migration and disarrangement and abnormal ECM re-organization. Importantly, the altered expression of MMPs and TIMP-2 by DOCA-salt was effectively reversed in ClC-3 knock-out mice, which may be one of the mechanisms accounting for the protective effects of ClC-3 deficiency on vascular remodelling.
In addition, TGF-b has long been believed to be the most important ECM regulator. By binding to its transmembrane receptor, the activated TGF-b could further activate the signal intermediator called Smad, and then up-regulate the gene transcription of some ECM proteins, such as procollagens, 35 fibronectin, 36 and CTGF. 37 A number of evidence has suggested that activation of Smad3 cascade plays an essential role in renal fibrosis, 38 cardiac infarction, 39 and wound healing. 40 In DOCA-salt hypertension, it has been reported that renal functional and structural injuries are accompanied by increased production of ECM protein and activation of the TGF-b/Smad signalling pathway. 41 In VSMC, it has been shown that TGF-b can be activated by MMP-2, 42 and the ectopic expression of Smad3 mediates TGF-b-induced fibronectin synthesis, 43 suggesting that TGF-b/Smad3 pathway may also play an important role in vascular remodelling. Our present study here demonstrated that accompanied by ECM accumulation and cerebrovascular remodelling, TGF-b1 level in serum was significantly increased by DOCA-salt, which was inhibited by ClC-3 deficiency. Moreover, although the total protein level of Smad3 in basilar artery was up-regulated by DOCA-salt in both WT and ClC-3 2/2 mice, the expression of Smad3 phosphorylation was only significantly elevated in WT hypertensive mice. These results indicate that ClC-3 may be a key regulator for TGF-b/Smad3 cascade, and suppression of TGF-b/Smad3 signalling pathway may represent an important mechanism of ClC-3 modulation of ECM deposition and cerebrovascular remodelling by a mineralocorticoid.
Conclusion
The present study demonstrates, for the first time to our knowledge, that lack of ClC-3 in vivo attenuates cerebrovascular remodelling and reduces blood pressure in low-renin hypertension. Suppression of MMPs/TIMPs expression and TGF-b1/Smad3 signalling pathway may account for the beneficial effect of ClC-3 on preserving the structural integrity of basilar artery. The present study provides new mechanistic insights that inhibition of ClC-3 may be a rational therapeutic strategy for prevention of cerebrovascular remodelling and thus stroke. ClC-3 and cerebrovascular remodelling
